Neuroscience of aging

Memory Health Receives Third Patent For Role In The Prevention And/Or Treatment Of Neurodegenerative Disease

Retrieved on: 
Tuesday, July 27, 2021
Branches of biology, Cognitive disorders, Psychiatry, Neuroscience, Learning disabilities, Psychiatric diagnosis, Dementia, Alzheimer's disease, Neurodegeneration, Mild cognitive impairment, Disabilities affecting intellectual abilities, Neuroscience of aging

The Intellectual Property Office of Ireland granted Memory Health the patent bearing the specification number 87241, on June 15, 2021.

Key Points: 
  • The Intellectual Property Office of Ireland granted Memory Health the patent bearing the specification number 87241, on June 15, 2021.
  • Memory Health is the only supplement patented specifically for the prevention and/or treatment of neurodegenerative disease.
  • The term Neurodegenerative disease describes a range of conditions such as memory loss, mild cognitive impairment, dementia, and Alzheimer's disease, primarily affecting the neurons in the human brain.
  • Memory Health is the gold standard of brain supplementation, the only patented formula for the prevention and/or treatment of neurodegenerative disease, especially dementia, in human subjects.

Latest lecanemab data to be presented at the AD/PD™ congress

Retrieved on: 
Friday, March 5, 2021
Branches of biology, Psychiatric diagnosis, Biology, Aging-associated diseases, Cognitive disorders, Learning disabilities, Geriatrics, Alzheimer's disease, Neurodegeneration, Parkinson's disease, Gladstone Institutes, Neuroscience of aging

The International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders - which due to the ongoing COVID-19 pandemic will be held online - is a key scientific event with a focus on improving the treatment of Alzheimer's, Parkinson's and other related neurodegenerative diseases.

Key Points: 
  • The International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders - which due to the ongoing COVID-19 pandemic will be held online - is a key scientific event with a focus on improving the treatment of Alzheimer's, Parkinson's and other related neurodegenerative diseases.
  • BioArctic's poster presentation will focus on findings in a recent study of brain tissue samples and lecanemab which, together with the previously announced promising data from the large phase 2b study of lecanemab in early Alzheimer's disease, suggest that lecanemab could be of potential benefit for people with Down's syndrome with signs of functional or cognitive deterioration.
  • Eisai will present interim results from the ongoing open-label extension study of the Phase 2b study of lecanemab in early Alzheimer's disease.
  • The presentation will focus on preliminary results concerning the effect of lecanemab on amyloid levels in the brain in subjects who participated in the core imaging subgroup.

Latest lecanemab data to be presented at the AD/PD™ congress

Retrieved on: 
Friday, March 5, 2021
Branches of biology, Psychiatric diagnosis, Biology, Aging-associated diseases, Cognitive disorders, Learning disabilities, Geriatrics, Alzheimer's disease, Neurodegeneration, Parkinson's disease, Gladstone Institutes, Neuroscience of aging

The International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders - which due to the ongoing COVID-19 pandemic will be held online - is a key scientific event with a focus on improving the treatment of Alzheimer's, Parkinson's and other related neurodegenerative diseases.

Key Points: 
  • The International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders - which due to the ongoing COVID-19 pandemic will be held online - is a key scientific event with a focus on improving the treatment of Alzheimer's, Parkinson's and other related neurodegenerative diseases.
  • BioArctic's poster presentation will focus on findings in a recent study of brain tissue samples and lecanemab which, together with the previously announced promising data from the large phase 2b study of lecanemab in early Alzheimer's disease, suggest that lecanemab could be of potential benefit for people with Down's syndrome with signs of functional or cognitive deterioration.
  • Eisai will present interim results from the ongoing open-label extension study of the Phase 2b study of lecanemab in early Alzheimer's disease.
  • The presentation will focus on preliminary results concerning the effect of lecanemab on amyloid levels in the brain in subjects who participated in the core imaging subgroup.

Alzheimer's Disease: Pipeline Review, Developer Landscape and Competitive Insights 2019 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 2, 2019
Health, Pharmaceutical, Cognitive disorders, Psychiatric diagnosis, Psychiatry, Branches of biology, RTT, Learning disabilities, Medicine, Aging-associated diseases, Dementia, Alzheimer's disease, Neurodegeneration, Neuroscience of aging

The "Alzheimer's Disease: Pipeline Review, Developer Landscape and Competitive Insights" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Alzheimer's Disease: Pipeline Review, Developer Landscape and Competitive Insights" report has been added to ResearchAndMarkets.com's offering.
  • Alzheimer's disease is a neurodegenerative condition characterized by progressive memory loss, cognitive dysfunction and dementia.
  • Currently, it is the most commonly reported neurodegenerative disorder across the world, and the sixth leading cause of death in the US.
  • It was estimated that, in 2018, nearly 5.7 million Americans (considering all age groups) were living with Alzheimer's disease.